KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) Equity Average (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Equity Average for 14 consecutive years, with $27.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average changed 0.05% year-over-year to $27.4 million, compared with a TTM value of $27.4 million through Sep 2025, changed 0.05%, and an annual FY2024 reading of $28.3 million, down 12.06% over the prior year.
  • Equity Average was $27.4 million for Q3 2025 at TherapeuticsMD, up from $27.0 million in the prior quarter.
  • Across five years, Equity Average topped out at $33.6 million in Q1 2023 and bottomed at -$117.1 million in Q1 2022.
  • Average Equity Average over 5 years is -$8.0 million, with a median of $27.1 million recorded in 2025.
  • The sharpest move saw Equity Average plummeted 270.68% in 2021, then skyrocketed 536.77% in 2023.
  • Year by year, Equity Average stood at -$75.5 million in 2021, then skyrocketed by 91.3% to -$6.6 million in 2022, then surged by 536.77% to $28.7 million in 2023, then fell by 5.01% to $27.2 million in 2024, then rose by 0.5% to $27.4 million in 2025.
  • Business Quant data shows Equity Average for TXMD at $27.4 million in Q3 2025, $27.0 million in Q2 2025, and $27.1 million in Q1 2025.